Cover Image
市場調查報告書

AiCuris GmbH & Co. KG:產品平台分析

AiCuris GmbH & Co. KG - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251640
出版日期 內容資訊 英文 38 Pages
訂單完成後即時交付
價格
Back to Top
AiCuris GmbH & Co. KG:產品平台分析 AiCuris GmbH & Co. KG - Product Pipeline Review - 2016
出版日期: 2016年02月24日 內容資訊: 英文 38 Pages
簡介

AiCuris GmbH & Co. KG是致力於研究開發攸關生命之傳染病治療用抗生物質及抗病毒藥的製藥公司。該公司的專業領域廣達藥理學、病毒學、細菌學、醫藥品化學、藥物動力學、臨床發展等多方面。該公司的開發中產品網羅了HCMV,HSV,HIV,B型及C型肝炎,院內細菌性感染疾病等症狀。

本報告提供AiCuris GmbH & Co. KG 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

AiCuris GmbH & Co. KG的基本資料

  • AiCuris GmbH & Co. KG概要
  • 主要資訊
  • 企業資料

AiCuris GmbH & Co. KG:R&D概要

  • 主要的治療範圍

AiCuris GmbH & Co. KG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

AiCuris GmbH & Co. KG:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

AiCuris GmbH & Co. KG:藥物簡介

  • pritelivir
  • AIC-284
  • AIC-649
  • AIC-277
  • AIC-499
  • Small Molecule 1 for Gram-Negative Bacterial Infections
  • Small Molecule 2 for Gram-Negative Bacterial Infections
  • Small Molecule for Bacteral Infections
  • Small Molecule for Gram-Positive Bacterial Infections
  • Small Molecule for Infectious Disease
  • Small Molecule for Viral Infections

AiCuris GmbH & Co. KG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

AiCuris GmbH & Co. KG:最近的開發平台趨勢

AiCuris GmbH & Co. KG:暫停中的計劃

AiCuris GmbH & Co. KG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07950CDB

Summary

Global Markets Direct's, 'AiCuris GmbH & Co. KG - Product Pipeline Review - 2016', provides an overview of the AiCuris GmbH & Co. KG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AiCuris GmbH & Co. KG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of AiCuris GmbH & Co. KG
  • The report provides overview of AiCuris GmbH & Co. KG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses AiCuris GmbH & Co. KG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features AiCuris GmbH & Co. KG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate AiCuris GmbH & Co. KG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for AiCuris GmbH & Co. KG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding AiCuris GmbH & Co. KG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AiCuris GmbH & Co. KG Snapshot
    • AiCuris GmbH & Co. KG Overview
    • Key Information
    • Key Facts
  • AiCuris GmbH & Co. KG - Research and Development Overview
    • Key Therapeutic Areas
  • AiCuris GmbH & Co. KG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • AiCuris GmbH & Co. KG - Pipeline Products Glance
    • AiCuris GmbH & Co. KG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • AiCuris GmbH & Co. KG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • AiCuris GmbH & Co. KG - Drug Profiles
    • pritelivir
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AIC-284
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AIC-649
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AIC-277
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AIC-499
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Infectious Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Gram-Negative Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Gram-Negative Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Gram-Positive Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Infectious Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AiCuris GmbH & Co. KG - Pipeline Analysis
    • AiCuris GmbH & Co. KG - Pipeline Products by Target
    • AiCuris GmbH & Co. KG - Pipeline Products by Route of Administration
    • AiCuris GmbH & Co. KG - Pipeline Products by Molecule Type
    • AiCuris GmbH & Co. KG - Pipeline Products by Mechanism of Action
  • AiCuris GmbH & Co. KG - Recent Pipeline Updates
  • AiCuris GmbH & Co. KG - Dormant Projects
  • AiCuris GmbH & Co. KG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AiCuris GmbH & Co. KG, Key Information
  • AiCuris GmbH & Co. KG, Key Facts
  • AiCuris GmbH & Co. KG - Pipeline by Indication, 2016
  • AiCuris GmbH & Co. KG - Pipeline by Stage of Development, 2016
  • AiCuris GmbH & Co. KG - Monotherapy Products in Pipeline, 2016
  • AiCuris GmbH & Co. KG - Out-Licensed Products in Pipeline, 2016
  • AiCuris GmbH & Co. KG - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • AiCuris GmbH & Co. KG - Phase II, 2016
  • AiCuris GmbH & Co. KG - Phase I, 2016
  • AiCuris GmbH & Co. KG - Preclinical, 2016
  • AiCuris GmbH & Co. KG - Discovery, 2016
  • AiCuris GmbH & Co. KG - Pipeline by Target, 2016
  • AiCuris GmbH & Co. KG - Pipeline by Route of Administration, 2016
  • AiCuris GmbH & Co. KG - Pipeline by Molecule Type, 2016
  • AiCuris GmbH & Co. KG - Pipeline Products by Mechanism of Action, 2016
  • AiCuris GmbH & Co. KG - Recent Pipeline Updates, 2016
  • AiCuris GmbH & Co. KG - Dormant Developmental Projects,2016

List of Figures

  • AiCuris GmbH & Co. KG - Pipeline by Top 10 Indication, 2016
  • AiCuris GmbH & Co. KG - Pipeline by Stage of Development, 2016
  • AiCuris GmbH & Co. KG - Monotherapy Products in Pipeline, 2016
  • AiCuris GmbH & Co. KG - Out-Licensed Products in Pipeline, 2016
  • AiCuris GmbH & Co. KG - Pipeline by Target, 2016
  • AiCuris GmbH & Co. KG - Pipeline by Route of Administration, 2016
  • AiCuris GmbH & Co. KG - Pipeline by Top 10 Molecule Type, 2016
  • AiCuris GmbH & Co. KG - Pipeline Products by Mechanism of Action, 2016
Back to Top